{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:16:03Z","timestamp":1785366963613,"version":"3.55.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalradiologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Radiology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.crad.2017.04.003","type":"journal-article","created":{"date-parts":[[2017,5,2]],"date-time":"2017-05-02T21:01:57Z","timestamp":1493758917000},"page":"521-533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors"],"prefix":"10.1016","volume":"72","author":[{"given":"F.","family":"Alessandrino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.H.","family":"Tirumani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.M.","family":"Krajewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.B.","family":"Shinagare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Jagannathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.H.","family":"Ramaiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.N.","family":"Di Salvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.crad.2017.04.003_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2214\/AJR.15.15480","article-title":"A new look at toxicity in the era of precision oncology: imaging findings, their relationship with tumour response, and effect on metastasectomy","volume":"207","author":"Howard","year":"2016","journal-title":"AJR Am J Roentgenol"},{"issue":"7","key":"10.1016\/j.crad.2017.04.003_bib2","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1148\/rg.347130090","article-title":"Update on the role of imaging in management of metastatic colorectal cancer","volume":"34","author":"Tirumani","year":"2014","journal-title":"RadioGraphics"},{"issue":"1","key":"10.1016\/j.crad.2017.04.003_bib3","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.crad.2017.04.003_bib4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.suc.2015.11.005","article-title":"Chemotherapy-associated hepatotoxicities","volume":"96","author":"White","year":"2016","journal-title":"Surg Clin North Am"},{"issue":"6","key":"10.1016\/j.crad.2017.04.003_bib5","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s13244-015-0436-7","article-title":"Cancer therapy related complications in the liver, pancreas, and biliary system: an imaging perspective","volume":"6","author":"Ngo","year":"2015","journal-title":"Insights Imaging"},{"issue":"2","key":"10.1016\/j.crad.2017.04.003_bib6","first-page":"198","article-title":"Hepatic fibrosis in children with acute leukemia after therapy with folic acid antagonists","volume":"59","author":"Colsky","year":"1955","journal-title":"AMA Arch Pathol"},{"issue":"1","key":"10.1016\/j.crad.2017.04.003_bib7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2214\/AJR.11.7432","article-title":"Decade of molecular targeted therapy: abdominal manifestations of drug toxicities \u2014 what radiologists should know","volume":"199","author":"Howard","year":"2012","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"10.1016\/j.crad.2017.04.003_bib8","first-page":"935","article-title":"Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia","volume":"8","author":"Cohen","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.crad.2017.04.003_bib9","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.crad.2017.04.003_bib10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.crad.2017.04.003_bib11","doi-asserted-by":"crossref","first-page":"815105","DOI":"10.1155\/2013\/815105","article-title":"Liver injury induced by anti-cancer chemotherapy and radiation therapy","volume":"2013","author":"Maor","year":"2013","journal-title":"Int J Hepatol"},{"issue":"7","key":"10.1016\/j.crad.2017.04.003_bib12","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMra052270","article-title":"Drug-related hepatotoxicity","volume":"354","author":"Navarro","year":"2006","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.crad.2017.04.003_bib13","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1111\/liv.12958","article-title":"Chronic liver injury induced by drugs: a systematic review","volume":"35","author":"Stine","year":"2015","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.crad.2017.04.003_bib14","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMra021844","article-title":"Drug-induced hepatotoxicity","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crad.2017.04.003_bib15","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1021\/tx0002583","article-title":"Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity","volume":"14","author":"Guengerich","year":"2001","journal-title":"Chem Res Toxicol"},{"issue":"6","key":"10.1016\/j.crad.2017.04.003_bib16","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/clpt.2011.58","article-title":"Case definition and phenotype standardization in DILI","volume":"89","author":"Aithal","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.crad.2017.04.003_bib17","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2214\/AJR.15.14459","article-title":"Imaging of fluid in cancer patients treated with systemic therapy: chemotherapy, molecular targeted therapy, and haematopoietic stem cell transplantation","volume":"205","author":"Keraliya","year":"2015","journal-title":"AJR Am J Rogentgenol"},{"issue":"3","key":"10.1016\/j.crad.2017.04.003_bib18","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1148\/radiol.2015141749","article-title":"Hepatic parenchymal heterogeneity on contrast-enhanced CT scans following oxaliplatin-based chemotherapy: natural history and association with clinical evidence of sinusoidal obstruction syndrome","volume":"276","author":"Han","year":"2015","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.crad.2017.04.003_bib19","doi-asserted-by":"crossref","first-page":"W15","DOI":"10.2214\/AJR.12.9498","article-title":"Liver metastases in the era of molecular targeted therapy: new faces of treatment response","volume":"201","author":"Shinagare","year":"2013","journal-title":"AJR Am J Rogentgenol"},{"issue":"2","key":"10.1016\/j.crad.2017.04.003_bib20","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1634\/theoncologist.6-2-162","article-title":"Hepatotoxicity of chemotherapy","volume":"6","author":"King","year":"2001","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.crad.2017.04.003_bib21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1148\/rg.2016150132","article-title":"Imaging of drug-induced complications in the gastrointestinal system","volume":"36","author":"McGettigan","year":"2016","journal-title":"RadioGraphics"},{"issue":"16","key":"10.1016\/j.crad.2017.04.003_bib22","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.3748\/wjg.v19.i16.2543","article-title":"Computed tomography findings for predicting severe acute hepatitis with prolonged cholestasis","volume":"19","author":"Park","year":"2013","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.crad.2017.04.003_bib23","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1148\/rg.296095513","article-title":"Diffuse liver disease: strategies for hepatic CT and MR imaging","volume":"29","author":"Boll","year":"2009","journal-title":"RadioGraphics"},{"issue":"1","key":"10.1016\/j.crad.2017.04.003_bib24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7863\/ultra.33.1.9","article-title":"Clinical problem solving: utility of sonography in oncologic patients","volume":"33","author":"Cooley","year":"2014","journal-title":"J Ultrasound Med"},{"issue":"5","key":"10.1016\/j.crad.2017.04.003_bib25","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/ncponc1087","article-title":"Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy","volume":"5","author":"Loriot","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"issue":"18","key":"10.1016\/j.crad.2017.04.003_bib26","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.3748\/wjg.v17.i18.2349","article-title":"Lapatinib-induced hepatitis: a case report","volume":"17","author":"Peroukides","year":"2011","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.crad.2017.04.003_bib27","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s10637-013-9939-6","article-title":"Ipilimumab associated hepatitis: imaging and clinicopathologic findings","volume":"31","author":"Kim","year":"2013","journal-title":"Invest New Drugs"},{"issue":"6","key":"10.1016\/j.crad.2017.04.003_bib28","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/bcp.12231","article-title":"Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy","volume":"77","author":"Iacovelli","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.crad.2017.04.003_bib29","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.ejca.2015.03.019","article-title":"Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients","volume":"51","author":"Powles","year":"2015","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.crad.2017.04.003_bib30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cld.2016.08.009","article-title":"Drug hepatotoxicity: newer agents","volume":"21","author":"Bunchorntavakul","year":"2017","journal-title":"Clin Liver Dis"},{"issue":"2","key":"10.1016\/j.crad.2017.04.003_bib31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.crad.2017.04.003_bib32","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crad.2017.04.003_bib33","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-230X-7-34","article-title":"Portal vein thrombosis; risk factors, clinical presentation and treatment","volume":"7","author":"Sogaard","year":"2007","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.crad.2017.04.003_bib34","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-230X-11-32","article-title":"Anastrozole-related acute hepatitis with autoimmune features: a case report","volume":"11","author":"Inno","year":"2011","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"10.1016\/j.crad.2017.04.003_bib35","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jhep.2012.07.031","article-title":"Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients","volume":"57","author":"Mahale","year":"2012","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.crad.2017.04.003_bib36","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1148\/radiology.202.2.9015061","article-title":"Fulminant hepatic failure: observation with serial CT","volume":"202","author":"Itai","year":"1997","journal-title":"Radiology"},{"key":"10.1016\/j.crad.2017.04.003_bib37","doi-asserted-by":"crossref","first-page":"78","DOI":"10.2214\/ajr.178.1.1780078","article-title":"The \u201cstarry sky\u201d liver with right-sided heart failure","volume":"178","author":"Abu-Judeh","year":"2002","journal-title":"AJR Am J Rogentgenol"},{"issue":"8","key":"10.1016\/j.crad.2017.04.003_bib38","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s10620-014-3106-6","article-title":"Imaging appearance in acute liver failure: correlation with clinical and pathology findings","volume":"59","author":"Romero","year":"2014","journal-title":"Dig Dis Sci"},{"issue":"21","key":"10.1016\/j.crad.2017.04.003_bib39","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.crad.2017.04.003_bib40","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1148\/rg.352140121","article-title":"Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events","volume":"35","author":"Kwak","year":"2015","journal-title":"RadioGraphics"},{"issue":"10","key":"10.1016\/j.crad.2017.04.003_bib41","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","article-title":"Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab","volume":"3","author":"Tirumani","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.crad.2017.04.003_bib42","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.crad.2017.04.003_bib43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.crad.2017.04.003_bib44","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1634\/theoncologist.2009-0152","article-title":"Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver","volume":"14","author":"Cleary","year":"2009","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.crad.2017.04.003_bib45","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/01.sla.0000193599.57858.9b","article-title":"CASH (chemotherapy-associated steatohepatitis) costs","volume":"243","author":"Fong","year":"2006","journal-title":"Ann Surg"},{"key":"10.1016\/j.crad.2017.04.003_bib46","first-page":"109","article-title":"Hepatic impairment during simultaneous administration of medroxyprogesterone acetate and tamoxifen in the treatment of endometrial and ovarian carcinoma","volume":"4","author":"Riippa","year":"1984","journal-title":"Anti-cancer Res"},{"key":"10.1016\/j.crad.2017.04.003_bib47","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.2006.08.8344","article-title":"Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women","volume":"25","author":"Ushijima","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.crad.2017.04.003_bib48","first-page":"61","article-title":"Tamoxifen therapy and hepatic steatosis","volume":"49","author":"Coskun","year":"2002","journal-title":"Neoplasma"},{"key":"10.1016\/j.crad.2017.04.003_bib49","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2214\/ajr.180.1.1800129","article-title":"Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy","volume":"180","author":"Nishino","year":"2003","journal-title":"AJR Am J Rogentgenol"},{"issue":"1","key":"10.1016\/j.crad.2017.04.003_bib50","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s13244-015-0447-4","article-title":"Systemic treatment in breast cancer: a primer for radiologists","volume":"7","author":"Michaels","year":"2016","journal-title":"Insights Imaging"},{"issue":"1","key":"10.1016\/j.crad.2017.04.003_bib51","first-page":"35","article-title":"Nonalcoholic fatty liver disease: diagnosis and management","volume":"88","author":"Wilkins","year":"2013","journal-title":"Am Fam Physician"},{"issue":"4","key":"10.1016\/j.crad.2017.04.003_bib52","doi-asserted-by":"crossref","first-page":"993","DOI":"10.2214\/AJR.07.2052","article-title":"Nonalcoholic fatty liver disease","volume":"190","author":"Lall","year":"2008","journal-title":"AJR Am J Rogentgenol"},{"key":"10.1016\/j.crad.2017.04.003_bib53","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1053\/gast.2002.35354","article-title":"The utility of radiological imaging in nonalcoholic fatty liver disease","volume":"123","author":"Saadeh","year":"2002","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.crad.2017.04.003_bib54","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/jclinpath-2013-201620","article-title":"Non-alcoholic fatty liver disease: noninvasive investigation and risk stratification","volume":"66","author":"Dyson","year":"2013","journal-title":"J Clin Pathol"},{"issue":"3","key":"10.1016\/j.crad.2017.04.003_bib55","doi-asserted-by":"crossref","first-page":"582","DOI":"10.2214\/AJR.11.6729","article-title":"MRI steatosis grading: development and initial validation of a color mapping system","volume":"198","author":"Qayyum","year":"2012","journal-title":"AJR Am J Rogentgenol"},{"issue":"3","key":"10.1016\/j.crad.2017.04.003_bib56","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2214\/AJR.09.2590","article-title":"Hepatic steatosis (fatty liver disease) in asymptomatic adults identified by unenhanced low-dose CT","volume":"194","author":"Boyce","year":"2010","journal-title":"AJR Am J Rogentgenol"},{"issue":"9","key":"10.1016\/j.crad.2017.04.003_bib57","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.7863\/jum.2002.21.9.1023","article-title":"Sonography of diffuse liver disease","volume":"21","author":"Tchelepi","year":"2002","journal-title":"J Ultrasound Med"},{"issue":"3","key":"10.1016\/j.crad.2017.04.003_bib58","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2214\/ajr.171.3.9725292","article-title":"Diagnostic criteria for fatty infiltration of the liver on contrast-enhanced helical CT","volume":"171","author":"Jacobs","year":"1998","journal-title":"AJR Am J Rogentgenol"},{"issue":"1","key":"10.1016\/j.crad.2017.04.003_bib59","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00330-010-1905-5","article-title":"The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis","volume":"21","author":"Bohte","year":"2011","journal-title":"Eur Radiol"},{"issue":"3","key":"10.1016\/j.crad.2017.04.003_bib60","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/MEG.0000000000000287","article-title":"Correlation of the controlled attenuation parameter with indices of liver steatosis in overweight or obese individuals: a pilot study","volume":"27","author":"Ferraioli","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.crad.2017.04.003_bib61","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/00004836-200508000-00012","article-title":"Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound","volume":"39","author":"Fishbein","year":"2005","journal-title":"J Clin Gastroenterol"},{"issue":"6","key":"10.1016\/j.crad.2017.04.003_bib62","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1586\/17474124.2016.1169919","article-title":"The cheating liver: imaging of focal steatosis and fatty sparing","volume":"10","author":"Dioguardi Burgio","year":"2016","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.crad.2017.04.003_bib63","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/j.transproceed.2005.03.025","article-title":"Time-related changes in the incidence, severity, and clinical outcome of hepatic veno-occlusive disease in haematopoietic stem cell transplantation patients during the past 10 years","volume":"37","author":"Kalayoglu-Besisik","year":"2005","journal-title":"Transplant Proc"},{"issue":"12","key":"10.1016\/j.crad.2017.04.003_bib64","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1002\/(SICI)1097-0142(19970615)79:12<2435::AID-CNCR21>3.0.CO;2-R","volume":"79","author":"Ortega","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.crad.2017.04.003_bib65","series-title":"Holland\u2013Frei Cancer Medicine","article-title":"Liver toxicity and haematopoietic stem cell transplantation","author":"DeLeve","year":"2003"},{"key":"10.1016\/j.crad.2017.04.003_bib66","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood.V85.11.3005.bloodjournal85113005","article-title":"The syndrome of hepatic veno-occlusive disease after marrow transplantation","volume":"85","author":"Bearman","year":"1995","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.crad.2017.04.003_bib67","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/annonc\/mdh095","article-title":"Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer","volume":"15","author":"Rubbia-Brandt","year":"2004","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.crad.2017.04.003_bib68","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1034\/j.1600-0609.2000.9r200.x","article-title":"Veno-occlusive disease of the liver after hemopoietic cell transplantation","volume":"64","author":"Carreras","year":"2000","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.crad.2017.04.003_bib69","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00007890-200207150-00011","article-title":"Prognostic value of Doppler-ultrasonography in hepatic veno-occlusive disease","volume":"74","author":"Lassau","year":"2002","journal-title":"Transplantation"},{"issue":"15","key":"10.1016\/j.crad.2017.04.003_bib70","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1200\/JCO.2009.27.5701","article-title":"Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury","volume":"28","author":"Overman","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.crad.2017.04.003_bib71","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1148\/radiol.13131810","article-title":"Chemotherapy-induced focal hepatopathy in patients with gastrointestinal malignancy: gadoxetic acid-enhanced and diffusion-weighted MR imaging with clinical\u2013pathologic correlation","volume":"271","author":"Han","year":"2014","journal-title":"Radiology"},{"issue":"2","key":"10.1016\/j.crad.2017.04.003_bib72","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.carj.2014.11.001","article-title":"Multimodality imaging of tumour thrombus","volume":"66","author":"Rohatgi","year":"2015","journal-title":"Can Assoc Radiol J"},{"issue":"6","key":"10.1016\/j.crad.2017.04.003_bib73","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2214\/AJR.12.10171","article-title":"Usefulness of conventional MRI sequences and diffusion-weighted imaging in differentiating malignant from benign portal vein thrombus in cirrhotic patients","volume":"201","author":"Sandrasegaran","year":"2013","journal-title":"AJR Am J Rogentgenol"},{"issue":"40","key":"10.1016\/j.crad.2017.04.003_bib74","doi-asserted-by":"crossref","first-page":"6556","DOI":"10.3748\/wjg.v12.i40.6556","article-title":"Portal thrombosis and steatosis after preoperative chemotherapy with FOLFIRI-bevacizumab for colorectal liver metastases","volume":"12","author":"Donadon","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.crad.2017.04.003_bib75","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1200\/JCO.2010.32.3220","article-title":"Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies","volume":"29","author":"Hurwitz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.crad.2017.04.003_bib76","doi-asserted-by":"crossref","first-page":"9457","DOI":"10.3748\/wjg.v21.i32.9457","article-title":"Contrast-enhanced ultrasound in differentiating malignant from benign portal vein thrombosis in hepatocellular carcinoma","volume":"21","author":"Taranti-no","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.crad.2017.04.003_bib77","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1055\/s-0034-1375963","article-title":"Drug-induced nodular regenerative hyperplasia","volume":"34","author":"Ghabril","year":"2014","journal-title":"Semin Liver Dis"},{"issue":"4","key":"10.1016\/j.crad.2017.04.003_bib78","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1148\/radiographics.22.4.g02jl17847","article-title":"Benign regenerative nodules in Budd\u2013Chiari syndrome and other vascular disorders of the liver: radiologic\u2013pathologic and clinical correlation","volume":"22","author":"Brancatelli","year":"2002","journal-title":"RadioGraphics"},{"issue":"4","key":"10.1016\/j.crad.2017.04.003_bib79","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2214\/ajr.178.4.1780877","article-title":"Large regenerative nodules in Budd\u2013Chiari syndrome and other vascular disorders of the liver: CT and MR imaging findings with clinicopathologic correlation","volume":"178","author":"Brancatelli","year":"2002","journal-title":"AJR Am J Rogentgenol"},{"issue":"13","key":"10.1016\/j.crad.2017.04.003_bib80","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1245\/s10434-015-4533-0","article-title":"Nodular regenerative hyperplasia in patients undergoing liver resection for colorectal metastases after chemotherapy: risk factors, preoperative assessment and clinical impact","volume":"22","author":"Vigan\u00f2","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.crad.2017.04.003_bib81","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1200\/JCO.2013.49.8543","article-title":"Nodular regenerative hyperplasia after treatment with trastuzumab emtansine","volume":"34","author":"Force","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.crad.2017.04.003_bib82","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/ajcp\/80.6.881","article-title":"A case of peliosis hepatis in association with tamoxifen therapy","volume":"80","author":"Loomus","year":"1983","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.crad.2017.04.003_bib83","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/gut.29.9.1265","article-title":"Case report: peliosis hepatis induced by 6-thioguanine administration","volume":"29","author":"Larrey","year":"1988","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.crad.2017.04.003_bib84","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ajg.2014.131","article-title":"Practice Parameters Committee of the American College of Gastroenterology. ACG Clinical Guideline: the diagnosis and management of idiosyncratic DILI","volume":"109","author":"Chalasani","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.crad.2017.04.003_bib85","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.5301\/tj.5000247","article-title":"Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib","volume":"101","author":"Brandi","year":"2015","journal-title":"Tumouri"},{"issue":"9","key":"10.1016\/j.crad.2017.04.003_bib86","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/jjco\/hyu086","article-title":"Fulminant hepatitis following crizotinib administration for ALK-positive non-small-cell lung carcinoma","volume":"44","author":"Sato","year":"2014","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.crad.2017.04.003_bib87","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.lungcan.2015.12.010","article-title":"Crizotinib-induced fatal fulminant liver failure","volume":"93","author":"van Geel","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.crad.2017.04.003_bib88","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.cgh.2007.04.014","article-title":"Fulminant hepatic failure secondary to erlotinib","volume":"5","author":"Liu","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.crad.2017.04.003_bib89","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.diii.2012.02.008","article-title":"Cirrhotic and malignant ascites: differential CT diagnosis","volume":"93","author":"Risson","year":"2012","journal-title":"Diagn Interv Imaging"},{"issue":"1","key":"10.1016\/j.crad.2017.04.003_bib90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.crad.2014.08.015","article-title":"Metastatic patterns of breast cancer subtypes: what radiologists should know in the era of personalized cancer medicine","volume":"70","author":"Chikarmane","year":"2015","journal-title":"Clin Radiol"},{"issue":"1","key":"10.1016\/j.crad.2017.04.003_bib91","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1148\/radiol.10092129","article-title":"CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity","volume":"258","author":"Torrisi","year":"2011","journal-title":"Radiology"},{"issue":"9","key":"10.1016\/j.crad.2017.04.003_bib92","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/bjs.7194","article-title":"Systematic review and meta-analysis of steatosis as a risk factor in major hepatic resection","volume":"97","author":"de Meijer","year":"2010","journal-title":"Br J Surg"},{"issue":"2","key":"10.1016\/j.crad.2017.04.003_bib93","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1245\/s10434-010-1317-4","article-title":"Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy","volume":"18","author":"Tamandl","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.crad.2017.04.003_bib94","first-page":"S1","article-title":"AASLD Position Paper: the management of acute liver failure: update 2011","author":"Lee","year":"2011","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.crad.2017.04.003_bib95","first-page":"837","article-title":"Prevention and management of adverse events related to regorafenib","volume":"22","author":"De Wit","year":"2014","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.crad.2017.04.003_bib96","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1148\/rg.296095514","article-title":"MR imaging and CT of the biliary tract","volume":"29","author":"Yeh","year":"2009","journal-title":"RadioGraphics"},{"key":"10.1016\/j.crad.2017.04.003_bib97","series-title":"Guidance for Industry","author":"Food and Drug Administration","year":"2009"},{"key":"10.1016\/j.crad.2017.04.003_bib98","unstructured":"U. S. Food and Drug Administration\/Center for Drug Evaluation and Research. Yervoy (ipilimumab), full prescribing information. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125377s073lbl.pdf. Accessed 17 October 2016."},{"key":"10.1016\/j.crad.2017.04.003_bib99","unstructured":"U. S. Food and Drug Administration\/Center for Drug Evaluation and Research. Tykerb (lapatinib) full prescribing information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022059s007lbl.pdf. Accessed 17 October 2016."},{"issue":"4","key":"10.1016\/j.crad.2017.04.003_bib100","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/bjh.12558","article-title":"BCSH\/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation","volume":"163","author":"Dignan","year":"2013","journal-title":"Br J Haematol"}],"container-title":["Clinical Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000992601730140X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000992601730140X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T16:34:39Z","timestamp":1757867679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000992601730140X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":100,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S000992601730140X"],"URL":"https:\/\/doi.org\/10.1016\/j.crad.2017.04.003","relation":{},"ISSN":["0009-9260"],"issn-type":[{"value":"0009-9260","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"Clinical Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.crad.2017.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}